Pyc Therapeutics Ltd has released a press release.
First Subject Dosed in PKD Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Placement of Shortfall
- Retail Entitlement Offer Booklet
- Completion of Institutional Entitlement Offer
- PYC Equity Raising Presentation
- PYC Equity Raising to Raise up to $146 Million
Later from PYC Therapeutics
- Completion of Entitlement Offer
- Presentation of Clinical Proof of Concept in Lead Program
- Approval to Escalate Dosing in Kidney Disease Trial
- SRC Approves Dose Escalation in ADOA Clinical Trial
- FDA Alignment on Registrational Trial Design RP11 Program
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics